Exploratory analysis shows pet response impacts progression-free survival and overall survival in patients, indicating its prognostic value.
Key Points
PET4-negative patients showed improved progression-free survival in both BV-CHP and CHOP groups, enhancing treatment efficacy.
Specifically, BV-CHP demonstrated a hazard ratio of 0.36 for PFS in PET4-negative patients compared to PET4-positive, indicating significant survival improvements.
This analysis evaluated interim PET scans after treatment cycles, highlighting the prognostic impact of early imaging on patient outcomes.
Overall survival was notably better in PET4-negative patients across both treatment arms, suggesting potential clinical utility of this biomarker.